Judith Leopold

A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer

Patricia LoRusso, S Krishnamurthi, John Rinehart et al. · Journal of Clinical Oncology · 2005 · 89 citations

Oral Pd 0325901, Pathology, Cancer Biology +18

DW-MRI as a Biomarker to Compare Therapeutic Outcomes in Radiotherapy Regimens Incorporating Temozolomide or Gemcitabine in Glioblastoma

Stefanie Galbán, Benjamin Lemasson, Terence M. Williams et al. · PLoS ONE · 2012 · 31 citations · Full text

DCE and DW‐MRI monitoring of vascular disruption following VEGF‐Trap treatment of a rat glioma model

Benjamin A. Hoff, Mahaveer S. Bhojani, John S. Rudge et al. · NMR in Biomedicine · 2011 · 28 citations · Full text

Oncologic Imaging, Sensitive Imaging Biomarkers, High-grade Gliomas +23

Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients

Sujatha Menon, Lloyd R. Whitfield, Seth Sadis et al. · Journal of Clinical Oncology · 2005 · 28 citations

Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer

Mary Smithson, Regina Irwin, Gregory Williams et al. · Neoplasia · 2022 · 21 citations · Full text